Željko Reiner - Selected Publications#

Professor Reiner has published more than 600 papers. According to the Google Scholar he has more than 116,000 citations (h-index 65, i10-index 182) of his scientific publications and is therefore the most cited Croatian scientist not only in the field of biomedicine but in all fields of science. He was the first author of the first European Guidelines (ESC/EAS) for the Management of Dyslipidaemia published in 2011, and of the second edition which he co-authored in 2016. He was the co-author of the Joint European Guidelines on Cardiovascular Disease Prevention in Clinical Practice published in 2007 and those those published in 2012 and reviewer of the all the guidelines which were published until today, including those in 2021.

The first guidelines published in 2011 are also his most cited paper (according to the Google Scolar 6871 times): Reiner Ž et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Europ Heart J 2011; 32 (14), 1769-1818.

Some of his most cited research papers are those based upon EUROASPIRE surveys where he was on the Steering committee, e.g.:

Reiner Ž et al. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries–findings from the EUROASPIRE IV survey. Atherosclerosis 2016; 246, 243-250.

Recently he was the first one to suggest the direct association between lipid-lowering drugs statins and COVID-19 virus: Reiner Ž et al. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci 2020; 16 (3), 490-496.

He participated in many major multinational studies and the most recently published one is: EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet. 2021 Nov 6;398(10312):1713-1725.

He was co-author of some most important consensus/position papers in the field of lipidology and atherosclerosis and we will mention just some more recenty published:

Averna M et al. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis. 2021 May;325:99-109. AND

Santos RD et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. 2016;

The Lancet Diabetes Endocrinol 4 (10), 850-861. AND

Moulin P et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an “FCS score”. Atherosclerosis 2018; 275, 265-272. AND

Katsiki N et al. Statin therapy in athletes and patients performing regular intense exercise - Position paper from the International Lipid Expert Panel (ILEP). Pharmacol Res. 2020 May;155:104719.

He was also the author of some most impotant review papers which had a huge impact on the field, e.g.:

Reiner Ž. Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol. 2017 Jul;14(7):401-411. AND

Reiner Ž. Management of patients with familial hypercholesterolaemia. Nat Rev Cardiol. 2015 Oct;12(10):565-75